Track Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ,Ltd.'s receivables ($260M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (September 2026), 1349.HK shows a receivables of $260M. That compares with $370M in the prior-year period — down 28.9% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, 1349.HK's receivables is now $260M (was $370M) — a 28.9% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ,Ltd. is outperforming or lagging.
Tracking 1349.HK's receivables over time shows whether Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ,Ltd. is scaling, shrinking, or reshaping that part of the business. The current reading is $260M That compares with $370M in the prior-year period — down 28.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this receivables page, Stockcircle has Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ,Ltd.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $260M) with ownership activity and broader fundamentals.